TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 16)

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET SCOPE

1.2.1 MARKETS COVERED

1.2.2 YEARS CONSIDERED FOR THE STUDY

1.3 CURRENCY

1.4 LIMITATIONS

1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY (Page No. - 19)

2.1 RESEARCH DATA

2.1.1 SECONDARY DATA

2.1.1.1 Key data from secondary sources

2.1.2 PRIMARY DATA

2.1.2.1 Key data from primary sources

2.1.2.2 Breakdown of primary sources

2.2 MARKET SIZE ESTIMATION

2.3 MARKET BREAKDOWN AND DATA TRIANGULATION

2.4 MARKET SHARE ESTIMATION

2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. - 28)

4 PREMIUM INSIGHTS (Page No. - 31)

4.1 IMMUNOTHERAPY DRUGS MARKET OVERVIEW

4.2 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE (2019)

4.3 GEOGRAPHIC SNAPSHOT OF THE IMMUNOTHERAPY DRUGS MARKET

4.4 PIPELINE OF PHASE 2/3 IMMUNOTHERAPY DRUGS

5 MARKET OVERVIEW (Page No. - 42)

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

5.2.1 DRIVERS

5.2.1.1 Increasing adoption of immunotherapy drugs over conventional treatment regimens

5.2.1.2 Rising prevalence of cancer and autoimmune & infectious diseases

5.2.1.3 Increasing demand for monoclonal antibodies and biosimilars

5.2.2 RESTRAINTS

5.2.2.1 Timeline issues, side-effects, and manufacturing complexities

5.2.2.2 High attrition rate in the product development cycle

5.2.3 OPPORTUNITIES

5.2.3.1 Increased demand for personalized medicines

5.2.3.2 High scope for growth in emerging economies

5.2.3.3 Development of affordable nanoparticles for deploying immunotherapies

5.2.4 CHALLENGES

5.2.4.1 High cost of immunotherapy treatment, regional disparities, and lack of insurance coverage

5.2.4.2 Side-effects and low efficacy of immunotherapy drugs

5.2.4.3 Lack of awareness

5.2.4.4 Delays in diagnosis and treatment

5.2.5 IMPACT OF THE COVID-19 PANDEMIC ON THE IMMUNOTHERAPY DRUGS MARKET

6 IMMUNOTHERAPY DRUGS MARKET, BY TYPE (Page No. - 51)

6.1 INTRODUCTION

6.2 MONOCLONAL ANTIBODIES

6.2.1 MONOCLONAL ANTIBODIES ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN 2019

6.3 CHECKPOINT INHIBITORS

6.3.1 CHECKPOINT INHIBITORS MARKET TO GROW OWING TO THEIR WIDE APPLICABILITY IN NUMEROUS CANCER TREATMENTS

6.4 INTERFERONS & INTERLEUKINS

6.4.1 INTERFERONS & INTERLEUKINS USE THE PATIENT�S IMMUNE SYSTEM, WHICH PROVIDES SIGNIFICANT BENEFITS

6.5 OTHER IMMUNOTHERAPIES

7 IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA (Page No. - 57)

7.1 INTRODUCTION

7.2 CANCER

7.2.1 MALIGNANT CANCERS

7.2.1.1 Malignant cancers held the largest share of the immunotherapy drugs market in 2019

7.2.2 BENIGN CANCERS

7.2.2.1 Availability of a range of drugs for benign cancer treatment supports market growth

7.3 AUTOIMMUNE & INFLAMMATORY DISEASES

7.3.1 STRONG DEMAND FOR IMMUNOTHERAPIES BOLSTERS MARKET GROWTH IN THIS SEGMENT

7.4 INFECTIOUS DISEASES

7.4.1 INCREASING PREVALENCE AND RISE IN R&D SUPPORT MARKET GROWTH

7.5 OTHER THERAPEUTIC AREAS

8 IMMUNOTHERAPY DRUGS MARKET, BY END USER (Page No. - 64)

8.1 INTRODUCTION

8.2 HOSPITALS

8.2.1 HOSPITALS ACCOUNTED FOR THE LARGEST SHARE OF THE IMMUNOTHERAPY DRUGS MARKET

8.3 CLINICS

8.3.1 CLINICS PROVIDE FOCUSED, PRIMARY-LEVEL CARE FOR PATIENTS AND CANNOT PROVIDE ADVANCED TREATMENTS

8.4 OTHER END USERS

9 IMMUNOTHERAPY DRUGS MARKET, BY REGION (Page No. - 68)

9.1 INTRODUCTION

9.2 NORTH AMERICA

9.2.1 US

9.2.1.1 US holds the largest share of the North American market

9.2.2 CANADA

9.2.2.1 Increasing prevalence of cancer and the growing availability of approved immunotherapy drugs to drive market growth

9.3 EUROPE

9.3.1 UK

9.3.1.1 The UK accounts for the largest share of the European market

9.3.2 GERMANY

9.3.2.1 New law for biosimilars in Germany to drive market growth

9.3.3 FRANCE

9.3.3.1 Initiatives by leading pharma players to drive the French market for immunotherapy drugs

9.3.4 ITALY

9.3.4.1 Availability of reimbursement drives the market in Italy

9.3.5 SPAIN

9.3.5.1 Increasing incidences of cancer to drive market growth during the forecast period

9.3.6 REST OF EUROPE

9.4 ASIA PACIFIC

9.4.1 CHINA

9.4.1.1 Rising prevalence of cancer and other infectious diseases to boost the adoption of immunotherapy in China

9.4.2 JAPAN

9.4.2.1 Universal health coverage boosts the market for immunotherapy drugs in Japan

9.4.3 INDIA

9.4.3.1 High number of cancer specialty care hospitals to support market growth

9.4.4 AUSTRALIA

9.4.4.1 Government initiatives to pave the way for the development of the Australian immunotherapy drugs market

9.4.5 REST OF ASIA PACIFIC

9.5 REST OF THE WORLD

9.5.1 MIDDLE EAST & AFRICA

9.5.1.1 Infrastructural growth and favorable socioeconomic trends will support market growth in the MEA

9.5.2 BRAZIL

9.5.2.1 Government support and player interest in Brazil will drive the market

9.5.3 REST OF LATIN AMERICA

10 COMPETITIVE LANDSCAPE (Page No. - 109)

10.1 INTRODUCTION

10.2 MARKET EVALUATION FRAMEWORK

10.3 REVENUE ANALYSIS OF TOP MARKET PLAYERS

10.4 COMPETITIVE LEADERSHIP MAPPING (OVERALL MARKET) (2019)

10.4.1 STARS

10.4.2 EMERGING LEADERS

10.4.3 PERVASIVE COMPANIES

10.4.4 EMERGING COMPANIES

10.5 COMPETITIVE SCENARIO

10.5.1 KEY PARTNERSHIPS AND COLLABORATIONS

10.5.2 KEY PRODUCT LAUNCHES

10.5.3 KEY ACQUISITIONS

10.5.4 KEY EXPANSIONS

11 COMPANY PROFILES (Page No. - 115)

(Business Overview, Products Offered, Recent Developments, MnM View)*

11.1 F. HOFFMANN-LA ROCHE

11.2 PFIZER

11.3 MERCK & CO

11.4 NOVARTIS INTERNATIONAL AG

11.5 JOHNSON & JOHNSON

11.6 SANOFI

11.7 GLAXOSMITHKLINE

11.8 ABBVIE

11.9 AMGEN

11.10 BOEHRINGER INGELHEIM

11.11 ASTRAZENECA

11.12 ELI LILLY AND COMPANY

11.13 IMMATICS BIOTECHNOLOGIES GMBH

11.14 GENMAB

11.15 BIONTECH SE

11.16 GILEAD SCIENCES

11.17 NBE THERAPEUTICS

11.18 TEVA PHARMACEUTICALS

11.19 BAYER AG

11.20 BRISTOL-MYERS SQUIBB

11.21 INCYTE CORPORATION

*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

12 APPENDIX (Page No. - 169)

12.1 DISCUSSION GUIDE

12.2 KNOWLEDGE STORE: MARKETSANDMARKETS� SUBSCRIPTION PORTAL

12.3 RELATED REPORTS

12.4 AUTHOR DETAILS



LIST OF TABLES (114 TABLES)

TABLE 1 GLOBAL CANCER INCIDENCE, 2018 VS. 2025

TABLE 2 GROWTH IN FDA PERSONALIZED MEDICINE APPROVAL RATE, 2005�2018

TABLE 3 COST OF KEYTRUDA, BY REGION (2018)

TABLE 4 CHECKPOINT INHIBITORS COVERED BY THE AUSTRALIAN PBS, AS OF JUNE 2019

TABLE 5 IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018�2025 (USD BILLION)

TABLE 6 THERAPEUTIC AREAS IN WHICH MONOCLONAL ANTIBODY THERAPIES ARE APPROVED

TABLE 7 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2018�2025 (USD BILLION)

TABLE 8 CHECKPOINT INHIBITORS MARKET, BY REGION, 2018�2025(USD BILLION)

TABLE 9 INTERFERONS & INTERLEUKINS MARKET, BY REGION, 2014�2021 (USD BILLION)

TABLE 10 OTHER IMMUNOTHERAPIES MARKET, BY REGION, 2018-2025 (USD BILLION)

TABLE 11 IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018�2025 (USD BILLION)

TABLE 12 IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY REGION, 2018�2025 (USD BILLION)

TABLE 13 IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018�2025 (USD BILLION)

TABLE 14 IMMUNOTHERAPY DRUGS MARKET FOR MALIGNANT CANCER, BY REGION, 2018�2025 (USD BILLION)

TABLE 15 IMMUNOTHERAPY DRUGS MARKET FOR BENIGN CANCER, BY REGION, 2018�2025 (USD BILLION)

TABLE 16 IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2018�2025 (USD BILLION)

TABLE 17 IMMUNOTHERAPY DRUGS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2018�2025 (USD BILLION)

TABLE 18 IMMUNOTHERAPY DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2018�2025 (USD BILLION)

TABLE 19 IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018-2025 (USD BILLION)

TABLE 20 IMMUNOTHERAPY DRUGS MARKET FOR HOSPITALS, BY REGION, 2018-2025 (USD BILLION)

TABLE 21 IMMUNOTHERAPY DRUGS MARKET FOR CLINICS, BY REGION, 2018�2025 (USD BILLION)

TABLE 22 IMMUNOTHERAPY DRUGS MARKET FOR OTHER END USERS, BY REGION, 2018�2025 (USD BILLION)

TABLE 23 IMMUNOTHERAPY DRUGS MARKET , BY REGION, 2018�2025 (USD BILLION)

TABLE 24 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2018�2025 (USD BILLION)

TABLE 25 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018�2025 (USD BILLION)

TABLE 26 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018�2025 (USD BILLION)

TABLE 27 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018�2025 (USD BILLION)

TABLE 28 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018�2025 (USD BILLION)

TABLE 29 NEW CANCER CASES AND DEATHS IN THE US, BY TYPE, 2020

TABLE 30 US: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018�2025 (USD BILLION)

TABLE 31 US: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018�2025 (USD BILLION)

TABLE 32 US: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018�2025 (USD BILLION)

TABLE 33 US: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018�2025 (USD BILLION)

TABLE 34 CANADA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018�2025 (USD BILLION)

TABLE 35 CANADA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018�2025 (USD BILLION)

TABLE 36 CANADA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018�2025 (USD BILLION)

TABLE 37 CANADA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018�2025 (USD BILLION)

TABLE 38 EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2018�2025 (USD BILLION)

TABLE 39 EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018�2025 (USD BILLION)

TABLE 40 EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018�2025 (USD BILLION)

TABLE 41 EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018�2025 (USD BILLION)

TABLE 42 EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018�2025 (USD BILLION)

TABLE 43 UK: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018�2025 (USD BILLION)

TABLE 44 UK: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018�2025 (USD BILLION)

TABLE 45 UK: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018�2025 (USD BILLION)

TABLE 46 UK: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018�2025 (USD BILLION)

TABLE 47 GERMANY: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018�2025 (USD BILLION)

TABLE 48 GERMANY: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018�2025 (USD BILLION)

TABLE 49 GERMANY: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018�2025 (USD BILLION)

TABLE 50 GERMANY: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018�2025 (USD BILLION)

TABLE 51 FRANCE: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018�2025 (USD BILLION)

TABLE 52 FRANCE: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018�2025 (USD BILLION)

TABLE 53 FRANCE: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018�2025 (USD BILLION)

TABLE 54 FRANCE: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018�2025 (USD BILLION)

TABLE 55 ITALY: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018�2025 (USD BILLION)

TABLE 56 ITALY: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018�2025 (USD BILLION)

TABLE 57 ITALY: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018�2025 (USD BILLION)

TABLE 58 ITALY: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018�2025 (USD BILLION)

TABLE 59 SPAIN: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018�2025 (USD BILLION)

TABLE 60 SPAIN: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018�2025 (USD BILLION)

TABLE 61 SPAIN: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018�2025 (USD BILLION)

TABLE 62 SPAIN: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018�2025 (USD BILLION)

TABLE 63 ROE: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018�2025 (USD BILLION)

TABLE 64 ROE: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018�2025 (USD BILLION)

TABLE 65 ROE: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018�2025 (USD BILLION)

TABLE 66 ROE: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018�2025 (USD BILLION)

TABLE 67 APAC: INCREASE IN HEALTH EXPENDITURE, BY COUNTRY (USD PER CAPITA)

TABLE 68 APAC: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2018�2025 (USD BILLION)

TABLE 69 APAC: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018�2025 (USD BILLION)

TABLE 70 APAC: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018�2025 (USD BILLION)

TABLE 71 APAC: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018�2025 (USD BILLION)

TABLE 72 APAC: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018�2025 (USD BILLION)

TABLE 73 CANCER CASES IN CHINA, 2018

TABLE 74 CHINA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018�2025 (USD BILLION)

TABLE 75 CHINA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018�2025 (USD BILLION)

TABLE 76 CHINA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018�2025 (USD BILLION)

TABLE 77 CHINA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018�2025 (USD BILLION)

TABLE 78 JAPAN: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018�2025 (USD BILLION)

TABLE 79 JAPAN: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018�2025 (USD BILLION)

TABLE 80 JAPAN: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018�2025 (USD BILLION)

TABLE 81 JAPAN: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018�2025 (USD BILLION)

TABLE 82 INDIA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018�2025 (USD BILLION)

TABLE 83 INDIA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018�2025 (USD BILLION)

TABLE 84 INDIA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018�2025 (USD BILLION)

TABLE 85 INDIA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018�2025 (USD BILLION)

TABLE 86 AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018�2025 (USD BILLION)

TABLE 87 AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018�2025 (USD BILLION)

TABLE 88 AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018�2025 (USD BILLION)

TABLE 89 AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018�2025 (USD BILLION)

TABLE 90 ROAPAC: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018�2025 (USD BILLION)

TABLE 91 ROAPAC: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018�2025 (USD BILLION)

TABLE 92 ROAPAC: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018�2025 (USD BILLION)

TABLE 93 ROAPAC: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018�2025 (USD BILLION)

TABLE 94 ROW: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2018�2025 (USD BILLION)

TABLE 95 ROW: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018�2025 (USD BILLION)

TABLE 96 ROW: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018�2025 (USD BILLION)

TABLE 97 ROW: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018�2025 (USD BILLION)

TABLE 98 ROW: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018�2025 (USD BILLION)

TABLE 99 MEA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018�2025 (USD BILLION)

TABLE 100 MEA: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018�2025 (USD BILLION)

TABLE 101 MEA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018�2025 (USD BILLION)

TABLE 102 MEA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018�2025 (USD BILLION)

TABLE 103 BRAZIL: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018�2025 (USD BILLION)

TABLE 104 BRAZIL: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018�2025 (USD BILLION)

TABLE 105 BRAZIL: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018�2025 (USD BILLION)

TABLE 106 BRAZIL: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018�2025 (USD BILLION)

TABLE 107 ROLATAM: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2018�2025 (USD BILLION)

TABLE 108 ROLATAM: IMMUNOTHERAPY DRUGS MARKET, BY THERAPEUTIC AREA, 2018�2025 (USD BILLION)

TABLE 109 ROLATAM: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY TYPE, 2018�2025 (USD BILLION)

TABLE 110 ROLATAM: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2018�2025 (USD BILLION)

TABLE 111 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS (2016�2019)

TABLE 112 PRODUCT LAUNCHES (2016�2019)

TABLE 113 ACQUISITIONS (2016�2019)

TABLE 114 EXPANSIONS (2016�2019)



LIST OF FIGURES (34 FIGURES)

FIGURE 1 RESEARCH DESIGN

FIGURE 2 PRIMARY SOURCES

FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION

FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS

FIGURE 5 ILLUSTRATIVE EXAMPLE OF F. HOFFMAN-LA ROCHE

FIGURE 6 DATA TRIANGULATION METHODOLOGY

FIGURE 7 IMMUNOTHERAPY DRUGS MARKET ANALYSIS, BY TYPE (2020)

FIGURE 8 IMMUNOTHERAPY DRUGS MARKET ANALYSIS, BY THERAPEUTIC AREA, 2020 VS. 2025 (USD BILLION)

FIGURE 9 IMMUNOTHERAPY DRUGS MARKET ANALYSIS, BY END USER, 2020 VS. 2025 (USD BILLION)

FIGURE 10 NORTH AMERICA DOMINATES THE MARKET, BUT APAC TO REGISTER THE HIGHEST GROWTH RATE

FIGURE 11 INCREASING ADOPTION OF IMMUNOTHERAPY DRUGS TO DRIVE THE MARKET

FIGURE 12 MONOCLONAL ANTIBODIES ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN IMMUNOTHERAPY DRUGS MARKET IN 2019

FIGURE 13 ASIA PACIFIC TO WITNESS THE HIGHEST GROWTH IN THE IMMUNOTHERAPY DRUGS MARKET FROM 2020 TO 2025

FIGURE 15 IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2019

FIGURE 16 NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET SNAPSHOT

FIGURE 17 APAC: IMMUNOTHERAPY DRUGS MARKET SNAPSHOT

FIGURE 18 MARKET EVALUATION FRAMEWORK: COLLABORATIVE EFFORT WAS A PROMINENT TARGET FOR MARKET COMPANIES

FIGURE 19 IMMUNOTHERAPY DRUGS MARKET IN 2019

FIGURE 20 COMPETITIVE LEADERSHIP MAPPING: IMMUNOTHERAPY DRUGS MARKET

FIGURE 21 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2019)

FIGURE 22 PFIZER: COMPANY SNAPSHOT (2019)

FIGURE 23 MERCK & CO: COMPANY SNAPSHOT (2019)

FIGURE 24 NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT (2019)

FIGURE 25 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2019)

FIGURE 26 SANOFI: COMPANY SNAPSHOT (2019)

FIGURE 27 GLAXOSMITHKLINE: COMPANY SNAPSHOT (2019)

FIGURE 28 ABBVIE: COMPANY SNAPSHOT (2019)

FIGURE 29 AMGEN: COMPANY SNAPSHOT (2019)

FIGURE 30 ASTRAZENECA: COMPANY SNAPSHOT (2019)

FIGURE 31 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2019)

FIGURE 32 GENMAB: COMPANY SNAPSHOT (2019)

FIGURE 33 BIONTECH SE: COMPANY SNAPSHOT (2019)

FIGURE 34 GILEAD SCIENCES: COMPANY SNAPSHOT (2019)